Isabel Fox is a mother, wellness coach, Peloton enthusiast and one of just a handful of female General Partners in the UK. Prior to founding Luminous Ventures, Isabel was head of Venture Capital at White Cloud Capital where she focused on early stage investments in life sciences and healthcare. With a background in investment banking and private equity turnarounds, Isabel founded and exited two corporate communications firms focused on the route to exit, co-founded two software start-ups (one exit) and been an active angel investor in the UK and US. She has worked in New York, San Francisco and London. At Luminous Ventures, Isabel has the opportunity to invest in visionary founders with breakthrough technologies, and backing deep-tech and science that matters.
Max was previously a healthcare and life science investor at White Cloud Capital, making venture and growth capital investments in Europe and Asia across a range of indications, technologies and services. Having graduated from the University of Cambridge, Max started out as a corporate lawyer at Slaughter and May in London, Milan and Tokyo, sitting in the TMT and IP group. There he worked on, among other things, technology IPOs and M&A, giving him a taste for the commercial and investment side. His experience in intellectual property and regulation is particularly useful for the deep technology companies in which Luminous invests. Outside of the office, Max is often to be found trail running in the mountains or (where he can't get away) the Surrey Hills.
Simon Hsu has worked in technology-related fields for 20 years, and has spent most of his career in Foxconn and Acer Group in Taiwan focussed on corporate venture and M&A. Meanwhile, as General Manager of Foxconn and Acer’s subsidiaries, he has also been responsible for handling restructuring and daily operations post-investment. He is based between London and Taiwan and has strong connections to top East Asia universities & suppliers. He supports Luminous's portfolio businesses in their expansion to Asia and he also sources opportunities and partners locally. While at Foxconn he was a Strategic Investment team leader and head of the Corporate Venture Capital Fund. Later, he was in charge of strategic planning at Acer’s Cloud Business. At Acer, besides handling the IPO of Acer’s subsidiaries, Acer Cyber Security and Acer Synergy Technology, he was also in charge of enriching the product portfolio and expanding the footprint via strategic investment. Recently, Simon Hsu joined iDSoftCapital Group as General Partner, which is a VC/PE founded by Stan Shih, Founder and Honorable Chairman of Acer Group. Simon Hsu graduated from NCTU, LSE, and NYU/HKUST respectively, with majors in technology management and finance studies, and a bachelor’s degree in engineering.
Alasdair is currently a Venture Partner at Luminous Ventures and Ada Ventures (two London based early-stage venture firms), an advisor to KdT Ventures (an Austin, Tx based early-stage VC firm) and Head of Business and Corporate Development for BIOS Health (a UK/US/CAN neural interface and therapeutics company). He was previously a Director in the investment team at Leaps, the disruptive innovation and venture capital arm of Bayer AG, a multinational pharmaceutical, crop science and consumer health conglomerate and was responsible for Huma/Medopad among others, within the Leaps portfolio. He concentrates on the intersection of information technology and life sciences, and holds a particular investment focus on deep tech in life sciences and healthcare, digital health, regenerative medicine and cellular therapies. Alasdair previously held a joint investment/operational (as senior management within invested portfolio companies) role in the life science teams of two leading European venture capital firms, Medicxi and Index Ventures, and completed investments into a number of companies including: Morphogen-IX, Epsilon-3 Bio, Methuselah Health, Z Factor, Padlock Therapeutics and Stealthyx Therapeutics. Alasdair graduated with an undergraduate degree in Law and Mandarin Chinese from the School of Oriental and African Studies, University of London and an MPhil in Bioscience Enterprise from the University of Cambridge. He was also a visiting student at Fudan University (Shanghai) and Beijing Normal University studying Mandarin Chinese.
Peter is a scientist discovering the potential of technology to disrupt traditionally siloed and deeply technical scientific industries. Despite his pivot away from his background in therapeutics, he still appraises deep technology platforms with the same rigour common to the biopharma industry. Whilst the inflections in deep tech may be different to therapeutics, a commitment to quality science, a thorough understanding of the patient or customer need, and a clear capital efficient plan to execute are commonalities. He currently works in corporate strategy at Synthace, and before this was working in healthcare investment roles and with deep technology start-up accelerators. He has a DPhil in Chemical Biology from Oxford University, a master’s in chemistry (top of year) from Warwick Uni and experience in biopharma R&D. Outside of work, Peter is a huge animal lover, his favourite animals being the Beagle and as per his namesake, the Heron. He is also passionate about spending time outdoors and as such loves spending his summers surfing.
Miao He is a scientist passionate about the potential of new technologies bringing changes to all aspects of our lives. Previously she worked as a Bioinformatics Scientist at Illumina, where she combined genetic and computational approaches to interpreting genomic sequencing data to help deliver better cancer management. At Illumina she worked with early members of Solexa and collaborated with key opinion leaders in academia and Genomics England on the 100,000 Genomes Project. Miao has consulted for Cancer Research UK and healthcare/biotech businesses and has worked in early-stage investing at OurCrowd, a venture capital firm in Israel. Miao has a Ph.D. in Molecular Biology from the University of Cambridge and an MBA from London Business School. Miao is the author of 14 peer-reviewed publications and has first-author papers in high-impact journals such as Nature Genetics. Her research has been featured in the Guardian, BBC News, LA Times etc.
Josh Liu, a Taiwan national, has an MBA from Imperial College, London. He worked at and co-founded a number of hardware start-ups, he is the founder of GoVelo, a stealth mode startup building intelligent bicycle parking solutions to help modern corporate buildings provide secure cycling-friendly workspaces. He is also a mentor for the Royal Academy of Engineering in the UK. Josh helps Luminous portfolio companies access what they need in Taiwan.
John has a long background in the UK VC space and has a well-earned reputation from his success. In parallel to working with Luminous, John will be running his own Seed fund, AI Seed. John has sat on both sides of the fence as both entrepreneur and investor. On the investing side, John is the former CEO of Capital Enterprise, co-founded the London Co-investment Fund and the Capital List, and was also Investor Director at Basestone.
On graduating from Oxford, James Joll joined the Financial Times eventually writing the Lex column before joining N.M.Rothscild & Sons where he was a director in the corporate finance department for ten years. He then joined Pearson plc acting as CFO for the last eleven years of his career. Thereafter he pursued a portfolio existence being chairman of AIB Asset Management and a non-executive director of a number of companies, including Equitas, the Lloyds pre 1992 reinsurance vehicle. He remains chairman of the trustees of the Pearson pension plan and paints in oils in the week-end.
Csaba has over two decades of investment experience in both the hedge fund and venture capital worlds. Prior to joining Luminous, Csaba founded Tiller Partners a Los Angeles-based venture capital firm that focuses on seed, early-stage venture and late-stage venture investments. Prior to that he was Partner and Co-CIO at the global macro hedge fund Commonwealth Opportunity Capital where he focused on asset allocation and risk management. Before that, he was co-founder of GATKO Partners, a global, top-down equity hedge fund with offices in London and Singapore. He holds an M.Sc. in Economics from the University of Budapest and attended the MBA Program at the New York University Stern School of Business.
I have been fortunate to have known Isabel Fox for almost 10 years. Isabel is one of the most connected people I know with a vast network of business and investment contacts. Isabel's understanding and support of early stage companies is fantastic, I would have no hesitation in recommending her to any entrepreneur or company looking for investment or strategic marketing support.